Sonu Hangma Subba

Sonu Hangma Subba

Auto-generated profile, based on publicly available information

Sonu Hangma Subba

Department of Community Medicine and Family Medicine, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2022 in Journal of Medical Virology
Verified
Journal Article
Open access
PDF file
SPSwayam Pragyan Parida
Swayam Pragyan Parida
DSDinesh Prasad Sahu
Dinesh Prasad Sahu
ASArvind Kumar Singh
Arvind Kumar Singh
GAG. Alekhya
G. Alekhya
SSSonu Hangma Subba
Sonu Hangma Subba
BPBinod Kumar Patro
Binod Kumar Patro
The study aimed to assess the adverse events following COVID‐19 vaccine (Covaxin) immunization at a tertiary care institution and also assess the predictors of the adverse events following immunization (AEFI). The prospective observational study was conducted in a tertiary care institute among the Covaxin beneficiaries between June 28 and September 6, 2021. A total of 1826 participants were assessed for any local or systemic adverse events after seven days of vaccination. A telephonic interview was conducted, and the beneficiaries were assessed according to the adverse event grading. A total of 1826 participants were assessed for AEFI, and 544 (29.8%) reported at least one of the AEFI. No severe adverse events were reported, and about 1.6% had moderate AEFI. Pain at the injection site (14.6%), fever (9.7%), and myalgia (5.9%) were the common adverse events reported by the participants. AEFI incidence was higher in the first dose (38.1%) when compared to the second dose (26.4%), and this finding was significant with a p < 0.001. The major factors associated with AEFI were female sex, history of an allergic reaction, presence of comorbidities, acute infection in the past 3 months, and intake of chronic medications. Precaution needs to be taken while vaccinating individuals having allergies, comorbidities, acute infection in the last 3 months, and individuals on chronic medication.

31 January 2022 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
PBPriyamadhaba Behera
Priyamadhaba Behera
ASArvind Kumar Singh
Arvind Kumar Singh
SSSonu Hangma Subba
Sonu Hangma Subba
AMArjun Mc
Arjun Mc
DSDinesh Prasad Sahu
Dinesh Prasad Sahu
GBGitanjali Batmanabane
Gitanjali Batmanabane
India approved COVID-19 vaccine called Covaxin, developed by the Indian Council of Medical Research and Bharat Biotech Ltd. The primary objective of the study was to estimate the effectiveness of Covaxin in preventing breakthrough SARS-CoV-2 infection in healthcare workers (HCWs). A test-negative matched case-control study was conducted among HCWs of tertiary care hospital in Eastern India. Any HCW who tested positive for COVID-19 using RT-PCR during April and May 2021 was taken as the case. The HCWs who tested negative for COVID-19 by RT-PCR were considered as controls after matching with the date of testing and profession of the cases. Vaccination data were collected from the institution’s vaccine database and recall. In case of discrepancy, it was confirmed from the CoWIN portal (cowin.gov.in). The sample size was 670 participants (335 pairs). Conditional logistic regression models were used to calculate the adjusted odds ratio for breakthrough SARS-CoV-2 infection. Vaccine effectiveness was calculated using the following formula: VE = (1-aOR) × 100%. Sensitivity analysis was done for effectiveness of Covaxin, excluding Covishield vaccination. The mean age of participants was 29.1 years (SD = 7.1), and the majority were males (55.2%). Among the study participants, 60% were completely vaccinated, 18.51% were partially vaccinated, and 21.49% were unvaccinated. After adjusting for age, gender, type of household and past history of COVID-19 disease in conditional logistic models, the vaccine effectiveness was 22% (aOR 0.78, 95% CI: 0.52–1.17; p = .233). Sensitivity analysis with Covaxin showed an effectiveness of 29% (aOR 0.71, 95% CI: 0.47–1.08; p = .114) for preventing breakthrough SARS-CoV-2 infection.

8 January 2022 in medRxiv
Verified
Preprint
Open access
PDF file
MAM. C. Arjun
M. C. Arjun
ASArvind Kumar Singh
Arvind Kumar Singh
DPDebkumar Pal
Debkumar Pal
KDKajal Das
Kajal Das
AGAlekhya Gajjala
Alekhya Gajjala
SSSonu Hangma Subba
Sonu Hangma Subba
Background Long COVID or long-term complication after COVID-19 has the ability to affect health and quality of life. Knowledge about the burden and predictors could aid in their prevention and management. Most of the studies are from high-income countries and focus on severe cases. We did this study to estimate the prevalence and identify the characteristics and predictors of Long COVID among our patients. Methodology We recruited adult (≥18 years) patients who were diagnosed as Reverse Transcription Polymerase Chain Reaction (RTPCR) confirmed SARS-COV-2 infection and were either hospitalized or tested on outpatient basis. Eligible participants were followed up telephonically after four weeks of diagnosis of SARS-COV-2 infection to collect data on sociodemographic, clinical history, vaccination history, Cycle threshold (Ct) values during diagnosis and other variables. Characteristics of Long COVID were elicited, and multivariable logistic regression was done to find the predictors of Long COVID. Results We have analyzed 487 individual data with a median follow-up of 44 days (Inter quartile range (IQR): 39,47). Overall, Long COVID was reported by 29.2% (95% Confidence interval (CI): 25.3%,33.4%) participants. Prevalence of Long COVID among patients with mild/moderate disease (n = 415) was 23.4% (95% CI: 19.5%,27.7%) as compared to 62.5% (95% CI: 50.7%,73%) in severe/critical cases(n=72). The most common Long COVID symptom was fatigue (64.8%) followed by cough (32.4%). Statistically significant predictors of Long COVID were - Pre-existing medical conditions (Adjusted Odds ratio (aOR)=2.00, 95% CI: 1.16,3.44), having a more significant number of symptoms during acute phase of COVID-19 disease (aOR=11.24, 95% CI: 4.00,31.51), two doses of COVID-19 vaccination (aOR=2.32, 95% CI: 1.17,4.58), the severity of illness (aOR=5.71, 95% CI: 3.00,10.89) and being admitted to hospital (Odds ratio (OR)=3.89, 95% CI: 2.49,6.08). Conclusion A considerable proportion of COVID-19 cases reported Long COVID symptoms. More research is needed in Long COVID to objectively assess the symptoms and find the biological and radiological markers.

21 June 2022 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
GAG. Alekhya
G. Alekhya
PGPrajna Paramita Giri
Prajna Paramita Giri
AMArjun M.C.
Arjun M.C.
BBBinod Kumar Behera
Binod Kumar Behera
SSSonu Hangma Subba
Sonu Hangma Subba
Vaccination is a critical tool in protecting against COVID-19. It is essential to know the time for each activity in a COVID-19 vaccination process for better management, especially during a pandemic. Thus, we conducted a time-motion study to identify activities that led to delayed/increased waiting time in an urban primary health center in Bhubaneswar, India. We observed 196 COVID-19 vaccine beneficiaries over one month (June 2021) from when they arrived at the vaccination center until they left the center. A data collection form and a Stopwatch were used to estimate the time taken for various activities involved in COVID-19 vaccine delivery. The time taken was expressed in mean and median. We also compared the time taken during the first and second doses using the Mann-Whitney U test. The total mean time spent at the vaccination center was 40:56 ± 20:52 minutes. The activity that took the longest was ‘waiting time in queue before vaccination’, which was 34:22 ± 20:56 min constituting 82% of the total time. The activity that took longer for the second dose than the first was the beneficiary verification in the Co-WIN portal with a median of 27 seconds and 36 seconds, respectively (p < .001). This study will help program managers formulate better strategies to improve the vaccination process making it more efficient.

19 July 2022 in Hospital Topics
Verified
Journal Article
Closed access
ASArvind Kumar Singh
Arvind Kumar Singh
MPManoj Kumar Panigrahi
Manoj Kumar Panigrahi
SPSomen Kumar Pradhan
Somen Kumar Pradhan
DPDebkumar Pal
Debkumar Pal
SSSonu H. Subba
Sonu H. Subba
AGAIIMS Bhubaneswar COVID-19 Study Group
AIIMS Bhubaneswar COVID-19 Study Group
In this retrospective observational study, we have performed a comparative analysis of the demographic, clinical and epidemiological characteristics of the HCWs affected with SARS-CoV-2 infection during first two waves in India. The overall prevalence of SARS-CoV-2 infection among HCWs was found to be 15.24% (14.20–16.33) and 23.38% (22.14–25.65) during first and second waves respectively. The second wave showed an adjusted odds ratio of 0.04(0.02–0.07) and 2.09(1.49–2.93) for hospitalization and being symptomatic, respectively. We detected significantly higher level of C-reactive protein (CRP) among admitted HCWs during the second wave (5.10 –14.60 mg/dl) as compared to the first wave (2.00 – 2.80 mg/dl). Our study found the relative risk of SARS-CoV-2 reinfection among HCWs during the second wave to be 0.68 [0.57–0.82, p < 0.001)]. Although, the prevalence of SARS CoV-2 infection and risk of being symptomatic was higher during second wave, the risk of hospitalization was less when compared with the first wave.

28 October 2025 in Preventive Medicine: Research & Reviews
Verified
Journal Article
Open access
SPSwayam Pragyan Parida
Swayam Pragyan Parida
MRMythry Ravichandran
Mythry Ravichandran
DPDebkumar Pal
Debkumar Pal
SKSwosti Kiran
Swosti Kiran
ASArvind Kumar Singh
Arvind Kumar Singh
SSSonu H. Subba
Sonu H. Subba
Introduction: The unexpected boom in international and domestic travel due to improved connectivity and accessibility compels us to think about the health of the travellers. Our study involved analyses of the data in the travel health clinic. Materials and Methods: A secondary data analysis of the data regarding yellow fever vaccination since January 2019 and the data regarding the travellers presenting to the travel health clinic from its inception on 19 November 2023 to 15 July 2024 was conducted. Results: The mean age of the participants was 35, with the majority of them being males. South Africa was the most common country of travel, followed by Nigeria. The common reasons for travel were occupation/business, followed by tourism. Less than 40% of the beneficiaries were only found to have normal BMI; more than three-fourths of the beneficiaries were either pre-hypertensive or hypertensive, and around 5% presented with elevated random blood sugar levels. Conclusions: The analysis in the paper provide a path for establishing travel health clinics. There is a need for health education activities on travel health services for travellers, which need to be accessible and affordable.